Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $15.9000 (-3.64%) ($15.6000 - $16.5000) on Sun. Jun. 16, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.25% (three month average) | RSI | 20 | Latest Price | $15.9000(-3.64%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | TNXP declines -6.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting TNXP price | TNXP will decline at least -2.625% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.625% (StdDev 5.25%) | Hourly BBV | 0 () | Intraday Trend | -3.6% | | | |
|
1 - 5 Day Possible Target | $-0.02(-100.13%) | Resistance Level | $17.08 | 5 Day Moving Average | $16.04(-0.87%) | 10 Day Moving Average | $16.16(-1.61%) | 20 Day Moving Average | $17.08(-6.91%) | To recent high | -43.4% | To recent low | 1.9% | Market Cap | $N/A | | | | Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |